Midatech Pharma PLC
LSE:MTPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Midatech Pharma PLC
Inventory
Midatech Pharma PLC
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Midatech Pharma PLC
LSE:MTPH
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Inventory
£6.7m
|
CAGR 3-Years
96%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Inventory
£74.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Inventory
£17.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
20%
|
|
Midatech Pharma PLC
Glance View
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 40 full-time employees. The company went IPO on 2014-12-08. The firm has developed three in-house technology platforms, each with its own mechanism to improve delivery of medications to sites of disease. The firm's platform includes Q-Sphera platform, MidaSolve platform and MidaCore platform. Q-Sphera platform is a micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). MidaSolve platform is a nanotechnology used to dissolve insoluble drugs, which can be administered in liquid form directly and locally into tumors. MidaCore platform is a nanotechnology used for targeting medications to sites of disease. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211, MTD214, MTD220, MTX213, MTX214, MTX216, MTX110, MTX110, MTX110 and MTX114.
